$LENZ Therapeutics receives FDA approval for VIZZ eye drops; high-risk biotech opportunity.

LENZ Therapeutics Inc. ($LENZ), a small-cap biotech company, has received FDA approval for its VIZZ eye drops. FDA approval is a significant bullish catalyst for biotech companies, often leading to substantial stock price increases, albeit with inherent high risk for small caps.